Objective To review recent advances in the epidemiology, pathobiology, and management
of weight gain and obesity in patients with schizophrenia and to evaluate the extent to which …

Fasting hyperglycemia, impaired glucose tolerance, prediabetes, and diabetes are
frequently present in patients treated with second-generation antipsychotics (SGAPs) for …

Atypical antipsychotics (AAPs) are the drug of choice in the management of mental illnesses
by virtue of their advantage over typical antipsychotics ie least tendency of producing …

Antipsychotic drugs (APDs) are widely prescribed to control various mental disorders. As
mental disorders are chronic diseases, these drugs are often used over a life-time. However …

The high prevalence of metabolic syndrome in persons with schizophrenia has spurred
investigational efforts to study the mechanism beneath its pathophysiology. Early psychosis …

Introduction: Patients living with schizophrenia have a marked risk of clinically significant
weight gain and obesity compared to the general population. The risks have been …

Schizophrenia (SCZ) is a serious mental illness that affects 1% of people worldwide. SCZ is
associated with a higher risk of developing metabolic disorders such as obesity …

Although second-generation antipsychotics induce severe weight gain and obesity, there is
a lack of detailed knowledge about the progressive development of antipsychotic-induced …

Deficits in neurite outgrowth and synaptogenesis have been recognized as an underlying
developmental aetiology of psychosis. Electrical stimulation promotes neuronal induction …

Olanzapine is the one of first line antipsychotic drug for schizophrenia and other serious
mental illness. However, it is associated with troublesome metabolic side-effects, particularly …